Ascendis Pharma A/S(ASND) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:00 PM ET (Korea 10/27 05:00)
Full metrics table
| Index | - | P/E | 18.68 | EPS (ttm) | 13.12 | Insider Own | 1.16% | Shs Outstand | 65.7M | Perf Week | 6.61% |
| Market Cap | 16.10B | Forward P/E | 23.95 | EPS next Y | -37.34% | Insider Trans | -2.49% | Shs Float | 64.9M | Perf Month | 8.67% |
| Enterprise Value | 15.68B | PEG | - | EPS next Q | 0.91 | Inst Own | 102.15% | Short Float | 5.37% | Perf Quarter | -3.65% |
| Income | 0.87B | P/S | 13.19 | EPS this Y | 487.63% | Inst Trans | 1.06% | Short Ratio | 5.02 | Perf Half Y | 8.16% |
| Sales | 1.22B | P/B | 9.8 | EPS next 5Y | - | ROA | 44.55% | Short Interest | 3.48M | Perf YTD | 14.96% |
| Book/sh | 25.01 | P/C | 17.34 | EPS past 3/5Y | 27.03% 14.76% | ROE | 121.87% | 52W High | -13.11% ($282.15) | Perf Year | 21.36% |
| Cash/sh | 14.14 | P/FCF | 41.4 | Sales past 3/5Y | 147.23% 152.45% | ROIC | 41.62% | 52W Low | 30.35% ($188.07) | Perf 3Y | 175.45% |
| Dividend Est. | - | EV/EBITDA | 107.06 | EPS Y/Y TTM | 379.16% | Gross Margin | 89.84% | Volatility(W/M) | 2.48% 2.58% | Perf 5Y | 75.43% |
| Dividend TTM | - | EV/Sales | 12.85 | Sales Y/Y TTM | 128.41% | Oper. Margin | 10.32% | ATR (14) | 6.6 | Perf 10Y | 1154.61% |
| Dividend Ex-Date | - | Quick Ratio | 2.32 | EPS Q/Q | 583.5% | Profit Margin | 70.99% | RSI (14) | 61.02 | Recom | 1.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.99 | Sales Q/Q | 120.22% | SMA20 | 6.37% ($230.47) | Beta | 0.41 | Target Price | $304.02 |
| Payout | - | Debt/Eq | 0.31 | Earnings | 2026/8/13 | SMA50 | 1.08% ($242.53) | Rel Volume | 0.79 | Prev Close | $243.37 |
| Employees | - | LT Debt/Eq | 0.27 | EPS/Sales Surpr. | 91.14% 3.86% | SMA200 | 3.3% ($237.32) | Avg Volume(3M) | 0.69M | Price | $245.15 |
| IPO | 2015/1/28 | Option/Short | Yes/Yes | Trades | 8837 | Volume | 545,077 | Change | 0.73% |
A Denmark-based biopharmaceutical company that develops and sells treatments for rare endocrine disorders, such as growth hormone deficiency, leveraging its proprietary drug delivery technology designed to extend the duration of efficacy.
Over the past 1 year, roughly in the middle
13% below its 1-year high.
Traded less than usual. That is 79% of its average volume.
ASND makes money exceptionally well
Of every $100 in sales, $10.32 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +487.6% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $2,395. Peers typically go for $2,295.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +75.4%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 102.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #15 of 594 in the industry
Based on market cap of $16B.
EXEL#14 Exelixis Inc $16B PER 20.4 ASND#15 Ascendis Pharma A/S $16B PER 18.7 
HALO#16 Halozyme Therapeutics Inc $15B PER 38.3 
JAZZ#17 Jazz Pharmaceuticals plc $13B PER 14.2 
BBIO#18 BridgeBio Pharma Inc $13B PER - 
FAQ
What kind of company is ASND?
ASND belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ASND?
The market cap of ASND is approximately $16.1B, ranking 676 within its sector.
What is the P/E ratio of ASND?
ASND has a P/E ratio of approximately 18.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ASND?
ASND has recorded a 52-week high of $282.15 and a low of $188.07.
